|
Apr 21
|
Sanofi and Regeneron’s dupilumab approved by FDA for urticaria
|
|
Apr 19
|
Regeneron announces FDA accepted Priority Review sBLA for EYLEA HD
|
|
Apr 19
|
Regeneron, Sanofi announce FDA approval of Dupixent for CSU
|
|
Apr 18
|
Regeneron Provides Update on EYLEA HD® (aflibercept) Injection 8 mg Supplemental Biologics License Application
|
|
Apr 18
|
Dupixent® (dupilumab) Approved in the U.S. as the First New Targeted Therapy in Over a Decade for Chronic Spontaneous Urticaria (CSU)
|
|
Apr 17
|
FDA to review Regeneron’s sBLA for aflibercept injection 8mg
|
|
Apr 17
|
EYLEA HD® (aflibercept) Injection 8 mg sBLA Accepted for FDA Priority Review for Both the Treatment of Macular Edema Following Retinal Vein Occlusion (RVO) and for Monthly Dosing in Approved Indications
|
|
Apr 15
|
Immuno-Oncology Stocks Q4 In Review: Exact Sciences (NASDAQ:EXAS) Vs Peers
|
|
Apr 14
|
Reflecting On Immuno-Oncology Stocks’ Q4 Earnings: Regeneron (NASDAQ:REGN)
|
|
Apr 7
|
4 Beaten-Down Stocks That Could Skyrocket by 50% to 543%, According to Wall Street
|
|
Apr 7
|
Immuno-Oncology Stocks Q4 Highlights: Incyte (NASDAQ:INCY)
|
|
Apr 5
|
Regeneron Pharmaceuticals (NasdaqGS:REGN) Drops 10% Over Last Week Despite Dupixent Approval in Japan
|
|
Apr 5
|
3 Growth Stocks That Have Turned $1,000 Into More Than $100,000 in 20 Years
|
|
Feb 24
|
Latest DB-OTO Results Demonstrate Clinically Meaningful Hearing Improvements in Nearly All Children with Profound Genetic Hearing Loss in CHORD Trial
|
|
Feb 24
|
Regeneron Pharmaceuticals (REGN): Among the Best Growth Stocks to Invest In According to Analysts
|
|
Feb 24
|
The Zacks Analyst Blog Highlights Merck, Sanofi, Regeneron and Ionis
|
|
Feb 21
|
2 Healthcare Stocks with Big Upside and 1 to Skip
|
|
Feb 18
|
FDA To Review Teva and Alvotech Drug That Could Compete With Regeneron's Eylea
|
|
Feb 18
|
SNY and REGN's Dupixent sBLA for Skin Disease Gets FDA's Priority Tag
|
|
Feb 18
|
FDA to review Sanofi and Regeneron’s Dupixent sBLA for bullous pemphigoid
|